Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study

Current Oncology

Volumn 21, Issue 3, 2014, Pages 125-133

  Orditura, M ^a   Galizia, G ^a   Di Martino, N ^a   Ancona, E ^b   Castoro, C ^b   Pacelli, R ^a   Morgillo, F ^a   Rossetti, S ^a   Gambardella, V ^a   Farella, A ^a   Laterza, M M ^a   Ruol, A ^b   Fabozzi, A ^a   Napolitano, V ^a   Iovino, F ^a   Lietoa, E ^a   Fei, L ^a   Conzo, G ^a   Ciardiello, F ^a   De Vita, F ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

FOLFOX4; Gastroesophageal junction cancer; Preoperative chemoradiotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DERMATITIS; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECHOGRAPHY; ESOPHAGITIS; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; HUMAN; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PATHOLOGY; PATIENT SELECTION; PILOT STUDY; RADIATION DOSE REDUCTION; RADIATION SAFETY; STOMATITIS; SURVIVAL; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TOXICITY TESTING; TREATMENT RESPONSE; TUMOR RECURRENCE;

EID: 84902682619     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1570     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 2009;71:127-64.
3. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-54.
4. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
5. Siewert JR, Stein HJ. Classifcation of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85: 1457-9.
6. Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surgery 2006;95:260-9.
7. Wilkinson NW, Howe J, Gay G, Patel Parekh L, Scott Conner C, Donohue J. Differences in the pattern of presentation and treatment of proximal and distal gastric cancer: results of the 2001 gastric patient care evaluation. Ann Surg Oncol 2008;15:1644-50.
8. Griffths EA, Pritchard SA, Mapstone NP, Welch IM. Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology-an update for the surgical oncologist. World J Surg Oncol 2006;4:82.
9. Dresner SM, Lamb PJ, Bennet MK, Hayes N, Griffn SM. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. Surgery 2001;129:103-9.
10. Wajman J, Bennett MK, Raimes SA, Griffn SM. The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer 2002; 86:1223-9.
11. Hingorani M, Crosby T, Maraveyas A, Dixit S, Bateman A, Roy R. Neoadjuvant chemoradiotherapy for resectable oesophageal and gastro-oesophageal junction cancer. Do we need another randomized trial? Clin Oncol (R Coll Radiol) 2011;23:696-705.
12. Stahl M, Walz MK, Stuschke M, et al. Phase iii comparison of preoperative chemotherapy compared with chemoradio-therapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-6.
13. Orditura M, De Vita F, Muto P, et al. Adjuvant chemoradio-therapy in patients with stage iii or iv radically resected gastric cancer: a pilot study. Arch Surg 2010;145:233-8.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7 th ed. New York, NY: Springer-Verlag; 2009.
15. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program (ctep). Common Toxicity Criteria (CTC). Ver. 2.0. Bethesda, MD: ctep; 1999. [Available online at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf; cited May 12, 2011]
16. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (rtog) and the European Organiza-tion for Research and Treatment of Cancer (eortc). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
17. Japanese Gastric Cancer Association. Japanese gastric cancer t reatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-23.
18. Yang K, Chen HN, Chen XZ, et al. Transthoracic resection versus non-transthoracic resection for gastroesophageal junction cancer: a meta-analysis. PLoS One 2012;7:e37698.
19. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemora-diotherapy of esophageal carcinoma. Cancer 1994;73:2680-6.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. Chan YH. Biostatistics 203. Survival analysis. Singapore Med J 2004;45: 249-56.
22. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for adenocarcinoma. N Engl J Med 1996;335:462-7.
23. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase iii trial of trimodality therapy with cisplatin, fuorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer. calgb 9781. J Clin Oncol 2008;26:1086-92.
24. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemo-radiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-13.
25. Burmeister BH, Smithers BM, Gebski V, et al. Su rger y alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase iii trial. Lancet Oncol 2005;6:659-68.
26. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemora-diotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925-30.
27. Reynolds JV, Ravi N, Hollywood D, et al. Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J Thorac Cardiovasc Surg 2006;132:549-55.
28. Van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preopera-tive chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84.
29. Pera M, Gallego R, Montagut C, et al. Phase ii trial of pre-operative chemoradiotherapy with oxaliplatin, cisplatin, and 5-fu in locally advanced esophageal and gastric cancer. Ann Oncol 2012;23:664-70.
30. Wahba HA, El-Hadaad HA, Abd-Ellatif EA. Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxali-platin in patients with locally advanced esophageal cancer. Med Oncol 2012;29:1693-8.
31. Chiarion-Sileni V, Innocente R, Cavina R, et al. Multi-center phase ii trial of chemo-radiotherapy with 5-fuorouracil, leu-covorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemother Pharmacol 2009; 63: 1111-19.
32. De Vita F, Orditura M, Martinelli E, et al. A multicenter phase ii study of induction chemotherapy with folfox-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer 2011;10 4:427-32.
33. Rivera F, Galan M, Tabernero J, et al. Phase ii trial of preop-erative irinotecan-cisplatin followed by concurrent irinote-can-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys 2009: 75:1430-6.
34. Ajani JA, Winter K, Okawara GS, et al. Phase ii trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (rtog 9904): quality of combined modality therapy and pathological response. J Clin Oncol 2006;24:3953-8.
35. Orditura M, Galizia G, Napolitano V, et al. Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esopha-geal cancer: a phase ii study. Cancer Invest 2010; 28:820-7.
36. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastro-esophageal adenocarcinoma: an fnclcc and ffcd multicenter phase iii trial. J Clin Oncol 2011; 29: 1715-21.